



(51) International Patent Classification:
A61K 38/18 (2006.01)

(21) International Application Number:
PCT/US2015/035818

(22) International Filing Date:
15 June 2015 (15.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/012,104 13 June 2014 (13.06.2014) US
62/047,995 9 September 2014 (09.09.2014) US
62/058,789 2 October 2014 (02.10.2014) US
62/142,812 3 April 2015 (03.04.2015) US

(71) Applicants: **SANTA MARIA BIOTHERAPEUTICS, INC.** [US/US]; 701 Gateway Blvd., Suite 200, South San Francisco, CA 94080 (US). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **HAQQ, Christopher, Michael**; c/o Santa Maria Biotherapeutics, Inc., 701 Gateway Blvd., Suite 200, South San Francisco, CA 94080 (US). **LATYPOV, Ramil**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(74) Agents: **KABLER, Kevin** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FORMULATED RECEPTOR POLYPEPTIDES AND RELATED METHODS




Figure 7

(57) Abstract: Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.